Brief: Gen Ilac Says Pharmaceutical Production Facility In Azerbaijan Targeted To Be Commissioned In October 2026
29/04/2026 16:28
April 29 (Reuters) - Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret GENIL.IS: GEN ILAC - PHARMACEUTICAL PRODUCTION FACILITY IN AZERBAIJAN TARGETED TO BE COMMISSIONED IN OCTOBER 2026 GEN ILAC - AIMS FOR THE EXPORT SHARE OF PRODUCTS MANUFACTURED AT PRODUCTION FACILITY IN ANKARA TO REACH 70% GEN ILAC - PERFORMANCE HAS EXCEEDED THE 30% LIRA BASED GROWTH TARGET SET AT BEGINNING OF 2026 GEN ILAC - PHASE-1 STUDIES FOR THE SUL-238 PROJECT COMPLETED, PHASE-2 STUDIES COMMENCED GEN ILAC - FOR GN-037 PROJECT DEVELOPED FOR PSORIASIS, PHASE-2 STUDIES COMPLETED WITH POSITIVE RESULTS Source text: nIKA44YcdN Further company coverage: GENIL.IS (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;; +48 58 7696600;))
Recent news on Gen Ilac ve Saglik Urunleri Sanayi Ticaret
See all newsBrief: Gen Ilac Says It Wins Pharmaceutical Tender In Kazakhstan, Expects $1.19 Million Sales Contribution In 2027
Brief: Gen Ilac Says It Participates In Kazakhstan Drug Procurement Tender Via Med Service Plus Authorized By Kazakhstan Representative Office Of Gen Ilac
Brief: Gen Ilac Says It Signs Supply And Distribution Agreement With Incyte On Oct 9
Brief: Gen Ilac Says It Completes Pharmaceutical Manufacturing Plant Investment In Azerbaijan
Brief: Gen Ilac Says It Is To Start Share Buyback Programme For Max 125 Mln Nominal Shares With Allocated Funds Of 1.5 Bln Lira